Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

16.50USD
26 Apr 2017
Change (% chg)

-- (--)
Prev Close
$16.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,019,443
52-wk High
$33.00
52-wk Low
$15.60

Select another date:

BRIEF-Acorda qtrly GAAP net loss $0.41 per diluted share

* Acorda provides financial and pipeline update for first quarter 2017

Acorda Therapeutics to cut 20 percent of workforce

Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.

Acorda Therapeutics to cut 20 pct of workforce

April 5 Acorda Therapeutics Inc will cut nearly 20 percent of its workforce as part of a cost reduction plan, the company said on Wednesday, less than a week after losing certain patents for its multiple sclerosis (MS) drug, Ampyra.

U.S. judge invalidates Acorda multiple sclerosis drug patents

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

U.S. judge invalidates Acorda multiple sclerosis drug patents

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

UPDATE 2-U.S. judge invalidates Acorda multiple sclerosis drug patents

March 31 A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

BRIEF-U.S. district court invalidates four Acorda Therapeutics Ampyra patents

* U.S. district court issues decision to invalidate four Ampyra patents; company will appeal ruling

U.S. judge invalidates Acorda multiple sclerosis drug patents

March 31 A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics related to its multiple sclerosis drug Ampyra.

BRIEF-Acorda announces long-term safety data for CVT-301

* New drug application (NDA) submission planned by end Q2 2017

Hedge fund manager Kyle Bass loses challenge to Acorda patents

By Jan Wolfe The U.S. Patent and Trademark Office on Thursday rejected hedge fund manager Kyle Bass' challenge to four patents on Acorda Therapeutics' flagship multiple sclerosis drug Ampyra.

Select another date:

More From Around the Web